Bright Minds Biosciences (DRUG) Competitors $33.63 -0.14 (-0.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$33.72 +0.09 (+0.28%) As of 08/1/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. VERV, ORIC, PROK, IMNM, ZYME, AKBA, MLYS, TRVI, LENZ, and NRIXShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Verve Therapeutics (VERV), Oric Pharmaceuticals (ORIC), ProKidney (PROK), Immunome (IMNM), Zymeworks (ZYME), Akebia Therapeutics (AKBA), Mineralys Therapeutics (MLYS), Trevi Therapeutics (TRVI), LENZ Therapeutics (LENZ), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Verve Therapeutics Oric Pharmaceuticals ProKidney Immunome Zymeworks Akebia Therapeutics Mineralys Therapeutics Trevi Therapeutics LENZ Therapeutics Nurix Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Is DRUG or VERV more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Bright Minds Biosciences' return on equity of -14.56% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% Verve Therapeutics -303.64%-35.81%-27.57% Do analysts rate DRUG or VERV? Bright Minds Biosciences currently has a consensus target price of $83.25, indicating a potential upside of 147.55%. Verve Therapeutics has a consensus target price of $14.57, indicating a potential upside of 30.92%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bright Minds Biosciences is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders believe in DRUG or VERV? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 19.3% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, DRUG or VERV? Bright Minds Biosciences has higher earnings, but lower revenue than Verve Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-93.42Verve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27 Which has more risk & volatility, DRUG or VERV? Bright Minds Biosciences has a beta of -6.01, meaning that its share price is 701% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Does the media favor DRUG or VERV? In the previous week, Verve Therapeutics had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 9 mentions for Verve Therapeutics and 0 mentions for Bright Minds Biosciences. Verve Therapeutics' average media sentiment score of 0.59 beat Bright Minds Biosciences' score of 0.00 indicating that Verve Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bright Minds Biosciences Neutral Verve Therapeutics Positive SummaryBright Minds Biosciences beats Verve Therapeutics on 10 of the 16 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$237.88M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-93.4117.6228.6723.80Price / SalesN/A269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book36.558.508.275.55Net Income-$2.06M-$55.06M$3.24B$259.03M7 Day Performance-5.16%-3.98%-3.63%-4.56%1 Month Performance20.06%9.59%4.40%4.49%1 Year Performance2,799.14%6.72%25.97%18.05% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences1.6407 of 5 stars$33.63-0.4%$83.25+147.5%+2,799.1%$237.88MN/A-93.41N/AVERVVerve Therapeutics3.3445 of 5 stars$11.13flat$14.57+30.9%N/A$992.16M$32.33M-5.27110News CoverageORICOric Pharmaceuticals4.5629 of 5 stars$11.18-2.3%$18.57+66.1%-4.6%$974.97MN/A-5.9880News CoveragePositive NewsPROKProKidney3.2547 of 5 stars$3.08-6.4%$6.25+102.9%+29.4%$962.97M$80K-5.133Upcoming EarningsGap DownIMNMImmunome2.0494 of 5 stars$10.84-0.3%$23.33+115.3%-29.7%$945.82M$9.04M-3.4140News CoveragePositive NewsGap DownZYMEZymeworks2.8532 of 5 stars$13.46+1.0%$21.00+56.0%+24.3%$937.93M$93.38M-8.97460Upcoming EarningsAKBAAkebia Therapeutics3.7162 of 5 stars$3.59+0.8%$6.75+88.0%+188.4%$934.98M$160.18M-17.09430News CoverageUpcoming EarningsMLYSMineralys Therapeutics2.54 of 5 stars$13.60-5.0%$32.25+137.1%+13.4%$933.31MN/A-3.6528News CoverageInsider TradeTRVITrevi Therapeutics2.4276 of 5 stars$7.64-2.9%$20.88+173.2%+136.5%$923.09MN/A-16.9820News CoverageUpcoming EarningsShort Interest ↑LENZLENZ Therapeutics1.5155 of 5 stars$31.51-0.3%$48.60+54.2%+21.7%$889.98MN/A-17.80110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionNRIXNurix Therapeutics2.4937 of 5 stars$11.93+3.6%$29.31+145.7%-48.6%$880.69M$88.38M-4.57300News CoverageAnalyst Forecast Related Companies and Tools Related Companies Verve Therapeutics Competitors Oric Pharmaceuticals Competitors ProKidney Competitors Immunome Competitors Zymeworks Competitors Akebia Therapeutics Competitors Mineralys Therapeutics Competitors Trevi Therapeutics Competitors LENZ Therapeutics Competitors Nurix Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
